Kineta Two, LLC

Kineta, Inc.

Kineta One, LLC

University of California

Illumigen Biosciences, Inc.

Kineta Chronic Pain, LLC

Kv1.3 Therapeutics, Inc.

Ib Security Holders LLC

Shawn P Iadonato

Charles Lee Magness

Christina A Scherer

Kristin M Bedard

Maralee McVean

Mark Branum

Kerry W Fowler

Gary Rosenberg

Thierry Guillaudeux

Amy Olson

P Campion Fellin

Myra Wang Imanaka

Eric J Tarcha

Tory Hagen

Ping Wang

K George Chandy

Ernesto Javier Munoz

Jeffrey Jerard Posakony

Sanjeev Kumar Upadhayay

Paolo Sassone-Corsi

Ernesto J Muñoz

Kristin Lynn Eckel-Mahan

Ikenna Madu

Jogesh Mukherjee

Jose Mercado

M Reza Mirbolooki

Shari Kaiser

Charles L Magness

Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an &#x3b1;9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the &#x3b1;9&#x3b1;10 subtype of the nAChR) in a subject.

Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Anti-viral compounds

Disclosed herein are methods of treating ophthalmic conditions such as dry eye and uveitis by administering a pharmaceutical composition including a toxin-based therapeutic peptide. The peptide can include an acid or amide at the C-terminus and can be attached to an organic or inorganic chemical entity that has an anionic charge.

Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof

Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.

SHK-based pharmaceutical compositions and methods of manufacturing and using the same

Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels

Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.

Methods and cells for identifying RIG-I pathway regulators

Isoflavone anti-viral compounds

Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.

Diarylpyridine anti-viral compounds

Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.

Mutations in OAS1 genes

A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.

Detection of mutations in a gene associated with resistance to viral infection, OAS1

Growing community of inventors

Seattle, WA, United States of America

Shawn P Iadonato